Teva considering $2B sale of active pharma ngredients unit | Seeking Alpha
DOJ orders Teva and Glenmark to pay millions in fines in drug price fixing settlment
Ukraine. 29th Apr, 2021. In this photo illustration, a Teva logo of an Israel pharmaceutical company seen displayed on a smartphone and a pc screen. Credit: Pavlo Gonchar/SOPA Images/ZUMA Wire/Alamy Live News
Teva's two new digital inhalers complete Digihaler product line | MobiHealthNews
Teva CEO Richard Francis on Q2 earnings beat
Teva Pharmaceuticals is found liable in the opioid crisis : NPR
Teva Pharmaceutical Industries Ltd.
Teva Defeats Patent Infringement Claims on Endocrine Drug | ...
Teva Pharmaceutical posts rise in Q3 2023 net income to $80m
Teva USA
Teva to pay $225M to settle cholesterol drug price-fixing charges | AP News
Teva Pharmaceuticals, NY reach opioid lawsuit settlements worth $523M - Top Class Actions
Company Update (NYSE:TEVA): Teva Pharmaceutical Industries Ltd (ADR) Sells Off Last of Specialty Global Women's Health Portfolio Assets in $1.38 Billion Deal
Teva to pay $225 million fine and divest cholesterol drug to settle price-fixing charges | CNN Business
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York state | CNN
Teva 'Plagued By Problems,' Downgraded On Lost MS Drug Patents, DOJ Probe | Stock News & Stock Market Analysis - IBD
Teva's Richard Francis launches 'pivot to growth' strategy | Fox Business Video
Teva Pharmaceuticals responsible for fueling opioid crisis, New York jury finds - JURIST - News
Teva Seeks New CFO as It Faces High Debt Levels, Opioid Litigation - WSJ
Watch Teva CEO on Second-Quarter, Potential DOJ Settlement - Bloomberg
Teva reports revenue increase, says it will sell API business
Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | Reuters
/cloudfront-us-east-2.images.arcpublishing.com/reuters/G5JWOXLOQZIDLHFUUAR3HXPXEQ.jpg "Teva says Israel-Hamas war not hurting production, eyes growth in 2024 | Reuters")
Teva says Israel-Hamas war not hurting production, eyes growth in 2024 | Reuters
Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 1-Year High at $13.50 - American Banking and Market News
